BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Efficacy and Safety of Primovist in Chinese Patients
Phase 3
Completed
- Conditions
- Known or Suspected Focal Liver Lesions
- Interventions
- Drug: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 234
- Registration Number
- NCT00526188
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Phase 3
Completed
- Conditions
- Brain Metastases
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 165
- Registration Number
- NCT00522951
Endometrial Safety Study
Phase 3
Completed
- Conditions
- Postmenopause
- Interventions
- Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)Drug: 0.5mg NETA / 1.0mg E2 (Activella)
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 662
- Registration Number
- NCT00522873
Capadenoson in Angina Pectoris
Phase 2
Withdrawn
- Conditions
- Chronic Stable Angina
- Interventions
- Drug: Capadenoson (BAY 68-4986)Drug: Placebo
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Bayer
- Registration Number
- NCT00518921
SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study
Phase 2
Completed
- Conditions
- Dysmenorrhea
- Interventions
- Drug: PlaceboDrug: SH T00186DFDrug: SH T04740BDrug: SH T04740F
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 249
- Registration Number
- NCT00511797
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Phase 3
Completed
- Conditions
- Moderate Risk of CVD
- Interventions
- Drug: Aspirin (Acetylsalicylic acid, BAYE4465)Drug: Placebo
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12546
- Registration Number
- NCT00501059
- Locations
- 🇺🇸
PharmaTrials, Inc., Perth Amboy, New Jersey, United States
🇺🇸Merit Medical Group, Inc., Richlands, Virginia, United States
🇺🇸Medical Research Trust, Boynton Beach, Florida, United States
HR-QoL and Sexuality in Mirena Inserted Contraception Users
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 141
- Registration Number
- NCT00498784
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Phase 3
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1280
- Registration Number
- NCT00494871
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: PlaceboDrug: Sorafenib (Nexavar, BAY43-9006)
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 458
- Registration Number
- NCT00494299
BAY12-8039: 5 Days for Sinusitis vs Placebo
Phase 3
Completed
- Conditions
- Sinusitis
- Interventions
- Drug: Moxifloxacin (Avelox, BAY12-8039)Drug: Placebo
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 374
- Registration Number
- NCT00492024
© Copyright 2025. All Rights Reserved by MedPath